What the research shows
What happens when you stop a GLP-1
Sources verified against the primary documents on 9 July 2026.
The short answer
Weight comes back. In the STEP 1 extension, participants who had lost 17.3% of their body weight on semaglutide regained 11.6 percentage points of it within a year of stopping — about two-thirds of the loss — and most cardiometabolic improvements reverted towards baseline. In SURMOUNT-4, people switched to placebo regained 14% of body weight while those who stayed on tirzepatide lost a further 5.5%.
Key facts
- STEP 1: lost on drug (68 wks)
- 17.3% of body weight
- STEP 1: regained 1 yr after stopping
- 11.6 percentage points
- SURMOUNT-4: switched to placebo
- +14.0% weight over 52 weeks
- SURMOUNT-4: stayed on drug
- −5.5% further
The withdrawal data
Two randomised trials answer this directly, and they agree.
The STEP 1 trial extension followed 327 participants for a year after both semaglutide and the lifestyle intervention were discontinued at week 68. On treatment they had lost a mean 17.3% of body weight. One year off it, they had regained 11.6 percentage points, leaving a net loss of 5.6% from baseline. Improvements in cardiometabolic risk factors seen at week 68 "reverted towards baseline for most variables".
SURMOUNT-4 made the comparison cleaner still. After a 36-week open-label lead-in on tirzepatide (mean loss 20.9%), participants were randomised to continue or switch to placebo. Over the next 52 weeks, those continuing lost a further 5.5%; those on placebo regained 14.0%. Of those who continued, 89.5% maintained at least 80% of their lead-in weight loss, against 16.6% of those switched to placebo.
Why this is not a failure of willpower
The drug does not teach the body a lesson it retains. It suppresses appetite and slows gastric emptying for as long as it is present, and its effects decay with its concentration. Remove it and the physiology that defended the higher weight is still there — arguably more insistent, since weight loss itself lowers energy expenditure and raises hunger signalling.
Read that way, the regain data are not a scandal. They are what a chronic-disease treatment looks like when it is stopped. Nobody is surprised when blood pressure rises after antihypertensives are discontinued.
What the data do settle is the question people ask most: whether a GLP-1 is a temporary intervention that resets something. On the published evidence, it is not.
The half-life means it lingers, then leaves
Semaglutide has a half-life of about a week, so it takes over a month to clear meaningfully. Appetite does not return the day after a missed dose, which can make the eventual regain feel sudden and inexplicable. It is neither.
What these trials do not tell you
They do not tell you whether a slower, structured taper changes the outcome — that has not been tested. They do not tell you whether people who build sustained changes in eating and training regain less; the STEP 1 extension withdrew the lifestyle intervention alongside the drug, so the two are confounded.
And they do not tell you what to do. Whether to continue, taper, or stop a prescribed medicine is a conversation with the clinician who prescribed it.
Compounds referenced in this guide
Semaglutide is used or studied for weight loss; glycemic control and related fat loss and metabolic health goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.
Tirzepatide is used or studied for significant weight loss; glucose control and related fat loss and metabolic health goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.
Liraglutide is used or studied for weight loss; glucose control and related fat loss and metabolic health goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.
Frequently asked questions
Will I regain weight if I stop taking semaglutide?
The trial evidence says most of it, yes. In the STEP 1 extension, participants regained 11.6 of the 17.3 percentage points they had lost within one year of stopping — roughly two-thirds — and cardiometabolic improvements reverted towards baseline for most measured variables.
How much weight do people regain after stopping tirzepatide?
In SURMOUNT-4, participants switched to placebo after a 36-week lead-in regained 14.0% of body weight over the following 52 weeks, while those who continued tirzepatide lost a further 5.5%. Only 16.6% of the placebo group maintained at least 80% of their initial loss, versus 89.5% of those who continued.
Is a GLP-1 a lifelong medication?
The withdrawal trials show the effect depends on continued presence of the drug, as with most treatments for chronic conditions. Whether any individual should remain on one indefinitely is a clinical decision that depends on their goals, response, tolerability, and risks — not something a website can answer.
Does tapering off slowly prevent weight regain?
Nobody knows. No randomized trial has tested a structured taper against abrupt discontinuation for weight maintenance. The published withdrawal studies stopped the drug outright. Claims that tapering preserves results are, at present, hypotheses.
Sources
Every link below was checked and resolved before publication. Where a claim could not be traced to a primary document, we left it out.
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022
- Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022
- DailyMed — official FDA drug labelling (U.S. National Library of Medicine)
Written by Pepperz Editorial and not medically reviewed — see our editorial standards. Educational reference only. Pepperz does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing recommendations.